Asciminib and Colchicine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Colchicine
Asciminib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Asciminib (Scemblix) can slow down two of your body's cleanup systems, an enzyme called CYP3A4 and a transporter called P-gp. Colchicine is removed from your body by both of those systems. So when you take them together, colchicine can build up higher than usual.
That matters because colchicine has a narrow safety window, meaning even a small increase can lead to more side effects like nausea, diarrhea, stomach pain, or muscle weakness. The good news is your care team knows how to handle this. They may adjust your colchicine dose or watch you a little more closely. Please don't change anything on your own. Just check in with your pharmacist or doctor.
Mechanism: Asciminib inhibits both CYP3A4 and P-gp. Colchicine is a substrate of both pathways and is a narrow-therapeutic-index (NTI) drug, so inhibition is expected to raise colchicine Cmax and AUC, increasing toxicity risk (GI effects, myelosuppression, neuromyotoxicity).
- Direction: increased colchicine exposure / effect (neither is a prodrug here)
- Severity: major; Evidence: theoretical; Onset: unspecified
- Management: Avoid colchicine with asciminib 200 mg BID. At all recommended asciminib doses, monitor closely for colchicine toxicity; colchicine dose may need individualized reduction, especially with renal or hepatic impairment. Consider alternatives where feasible.
What happens
Increased exposure to CYP3A4/P-gp substrates and increased risk of CYP3A4/P-gp substrates-related adverse effects
Interaction Deep Dive
Both CYP3A4 and P-gp are inhibited by asciminib. When asciminib is given together with a substrate that acts on both P-gp and CYP3A4 and has a narrow therapeutic index (NTI), the Cmax and AUC of that substrate rise, and even small shifts in concentration can trigger serious adverse reactions for such substrates. Do not combine asciminib dosed at 200 mg twice daily with CYP3A4 substrates that have an NTI. For patients receiving asciminib at any of the recommended doses along with a dual P-gp and CYP3A4 substrate that has an NTI, monitor carefully for adverse reactions1.
Why it happens (mechanism)
Inhibition of CYP3A4-substrate metabolism by asciminib; inhibition of P-gp mediated efflux transport by asciminib
How to manage this interaction
What your care team may do:
- Reduce or individualize your colchicine dose while you are on asciminib.
- Monitor you more closely for signs of too much colchicine, such as diarrhea, vomiting, stomach pain, or muscle weakness.
- Consider a different option in some cases, particularly at higher asciminib doses.
What you should do: Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Let your pharmacist or doctor know you take both drugs, and report any new stomach upset, muscle aches, unusual tiredness, or signs of infection promptly.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) When midazolam, a CYP3A4 substrate, was given together with asciminib 40 mg twice daily, the midazolam AUC (infinity) and Cmax rose by 28% and 11%, respectively. With asciminib at 80 mg once daily, the midazolam AUC (infinity) and Cmax rose by 24% and 17%, respectively, and at 200 mg twice daily they rose by 88% and 58%, respectively 1.
Common questions
Can I take Asciminib and Colchicine together?
Asciminib can raise colchicine levels and side effects; your care team may lower your colchicine dose or watch you more closely, so keep taking both as prescribed and report any stomach upset or muscle weakness. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Asciminib and Colchicine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Asciminib and Colchicine interaction managed?
What your care team may do: Reduce or individualize your colchicine dose while you are on asciminib. Monitor you more closely for signs of too much colchicine, such as diarrhea, vomiting, stomach pain, or muscle weakness. Consider a different option in some cases, particularly at higher asciminib doses. What you should do: Keep taking both exactly as prescribed unless your prescriber tells you oth… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Asciminib or Colchicine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: SCEMBLIX(R) oral tablets, asciminib oral tablets. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2023. DailyMed
Keep reading about Colchicine
Keep reading about Asciminib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist